Pα+ Psychedelic Bulletin #174: Psilocybin Outperforms Escitalopram After 6 Months… or Does It? Survey Results Reveal Healthcare Practitioner Attitudes to Psychedelics; and more… – Psychedelic Alpha

In this Issue

Six-Month Follow-Up Data Shows Psilocybin Outperforms Escitalopram… or Does It?
Survey Reveals Healthcare Practitioner Attitudes to Psychedelics
MIND Foundation Plots 700-Patient Psilocybin Study
Beckley Psytech-affiliated Study of Low-Dose Psilocybin for Headache Disorder Terminated Due to Recruitment Difficulties
More Headlines

***

Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.

Already a member? Log In

✓   Regular Bulletins covering key topics and trends in the psychedelics space
✓   Regular articles and deep dives across psychedelic research, policy and business
✓   Interviews with insiders
✓   Monthly interactive database and commentary on psychedelic patents
✓   Quick-take analysis of major developments
✓   A Library of primers and explainers
✓   Access to our full back catalogue

Learn more about Pα+

100,000 models show that not much was learned about stopping the Covid-19 pandemic

In the midst of the Covid-19 pandemic, scientists and public health institutions made bold claims about the effectiveness of various policy responses such as closing

June 5, 2024

Largest study using machine learning in neuroimaging sets new benchmark for major depression diagnosis

A benchmark classification of major depressive disorder (MDD) using machine learning (ML).

January 15, 2024

The Endpoints Slack interview: DA Wallach on music and science parallels, pharma’s biggest disruption, and investing in Elon

DA Wallach has an unusual résumé. The Harvard graduate played in an indie pop band called Chester French that toured with Lady Gaga and Blink-182.

February 29, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.